XTL Biopharmaceuticals Ltd. Culture Company

Mr. Ronen Kantor, Adv serves as Company Secretary of XTL Biopharmaceuticals Ltd. Mr. Kantor serves as Secretary of OphthaliX Inc. He is a Legal Professional of Naveh, Kantor, Even-Har Law Offices.

Mr. David Kestenbaum has been the Chief Financial Officer at XTL Biopharmaceuticals Ltd. since January 5, 2014. Mr. Kestenbaum serves as Chief Financial Officer of ZenithSolar Ltd. He has over 25 years of Financial Management experience in the US and Israel. He served as the Chief Financial Officer of the Israeli operations of several multinational companies including Unilever, The Stanleyworks and Johnson & Johnson. He is a US Certified Public Accountant. He holds a B.Sc. in Accounting from Yeshiva University (NY), and an MBA in Finance and International Business from Columbia University (NY).

Dr. Daphna Paran, MD, has been the Medical Director at XTL Biopharmaceuticals Ltd. since March 04, 2016. Dr. Paran is an internal medicine and rheumatology specialist. She has significant experience in the treatment of lupus patients, has published extensively on the subject and has been involved in several clinical studies in the search for viable treatment options for this difficult disease. Dr. Paran has over 20 years of rheumatology expertise with a focus on lupus. She is a Senior Lecturer at Tel Aviv University, the Head of the lupus clinic, Head of the rheumatology day care unit and the Deputy head of the Department of Rheumatology at the Tel Aviv Medical Center (Ichilov Hospital). She trained in lupus and the antiphospholipid syndrome at the lupus unit, Rayne Institute, St. Thomas' Hospital in London and has published or co-authored over 60 articles in the field of lupus and rheumatology. Dr. Paran completed her medical studies at Ben Gurion University.